[SCHEDULE 13G] Tango Therapeutics, Inc. Passive Investment Disclosure (>5%)
Rhea-AI Filing Summary
The Vanguard Group reported beneficial ownership of 6,750,977 shares of Tango Therapeutics Inc common stock, representing 5.01% of the class as of 12/31/2025. Vanguard reports no sole voting or dispositive power, with shared voting power over 742,606 shares and shared dispositive power over all 6,750,977 shares.
The shares are held on behalf of Vanguard’s clients, including registered investment companies and other managed accounts, and no single other person has an interest in more than 5% of the class. Vanguard states the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Tango Therapeutics. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
Positive
- None.
Negative
- None.